These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 12756053

  • 1. Use of basiliximab in pediatric liver transplantation for Langerhans cell histiocytosis.
    Rajwal SR, Stringer MD, Davison SM, Gerrard M, Glaser A, Tanner MS, McClean P.
    Pediatr Transplant; 2003 Jun; 7(3):247-51. PubMed ID: 12756053
    [Abstract] [Full Text] [Related]

  • 2. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children.
    Newell KA, Alonso EM, Kelly SM, Rubin CM, Thistlethwaite JR, Whitington PF.
    J Pediatr; 1997 Jul; 131(1 Pt 1):98-104. PubMed ID: 9255199
    [Abstract] [Full Text] [Related]

  • 3. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients.
    Ganschow R, Grabhorn E, Schulz A, Von Hugo A, Rogiers X, Burdelski M.
    Pediatr Transplant; 2005 Dec; 9(6):741-5. PubMed ID: 16269045
    [Abstract] [Full Text] [Related]

  • 4. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G, Walsh G, Deshpande P, Koffman G.
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [Abstract] [Full Text] [Related]

  • 5. First experience with basiliximab in pediatric liver graft recipients.
    Ganschow R, Broering DC, Stuerenburg I, Rogiers X, Hellwege HH, Burdelski M.
    Pediatr Transplant; 2001 Oct; 5(5):353-8. PubMed ID: 11560755
    [Abstract] [Full Text] [Related]

  • 6. Late-onset graft-versus-host disease after pediatric living-related liver transplantation for Langerhans cell histiocytosis.
    Yuksekkaya HA, Arikan C, Tumgor G, Aksoylar S, Kilic M, Aydogdu S.
    Pediatr Transplant; 2011 Sep; 15(6):E105-9. PubMed ID: 21884342
    [Abstract] [Full Text] [Related]

  • 7. Basiliximab monotherapy following B-cell lymphoma after pediatric liver transplantation and anti-CD20 therapy.
    Venzke A, Ganschow R, Grabhorn E, Rogiers X, Burdelski M.
    Pediatr Transplant; 2003 Oct; 7(5):404-7. PubMed ID: 14738304
    [Abstract] [Full Text] [Related]

  • 8. Concomitant basiliximab with low-dose calcineurin inhibitors in children post-liver transplantation.
    Arora N, McKiernan PJ, Beath SV, deVille de Goyet J, Kelly DA.
    Pediatr Transplant; 2002 Jun; 6(3):214-8. PubMed ID: 12100505
    [Abstract] [Full Text] [Related]

  • 9. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
    Sugiyama K, Isogai K, Horisawa S, Toyama A, Satoh H, Saito K, Nakagawa Y, Tasaki M, Takahashi K, Hirano T.
    Cell Transplant; 2012 Jun; 21(2-3):565-70. PubMed ID: 22793066
    [Abstract] [Full Text] [Related]

  • 10. Basiliximab treatment for steroid-resistant rejection in pediatric patients following liver transplantation for acute liver failure.
    Shigeta T, Sakamoto S, Uchida H, Sasaki K, Hamano I, Kanazawa H, Fukuda A, Kawai T, Onodera M, Nakazawa A, Kasahara M.
    Pediatr Transplant; 2014 Dec; 18(8):860-7. PubMed ID: 25311536
    [Abstract] [Full Text] [Related]

  • 11. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months.
    Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR.
    Transplant Proc; 2006 Dec; 38(10):3633-5. PubMed ID: 17175352
    [Abstract] [Full Text] [Related]

  • 12. Induction with basiliximab reduces acute rejection in pediatric liver transplant patients treated with tacrolimus and steroids.
    Asensio M, Margarit C, Chavez R, Ortega J, Charco R, Iglesias J.
    Transplant Proc; 2002 Aug; 34(5):1970-1. PubMed ID: 12176650
    [No Abstract] [Full Text] [Related]

  • 13. Analysis of rabbit anti-thymocyte globulin vs basiliximab induction in pediatric liver transplant recipients.
    Newland DM, Royston MJ, McDonald DR, Nemeth TL, Wallace-Boughter K, Carlin K, Horslen S.
    Pediatr Transplant; 2019 Dec; 23(8):e13573. PubMed ID: 31512802
    [Abstract] [Full Text] [Related]

  • 14. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience.
    Aw MM, Taylor RM, Verma A, Parke A, Baker AJ, Hadzic D, Muiesan P, Rela M, Heaton ND, Mieli-Vergani G, Dhawan A.
    Transplantation; 2003 Mar 27; 75(6):796-9. PubMed ID: 12660504
    [Abstract] [Full Text] [Related]

  • 15. Initial immunosuppression with or without basiliximab: a comparative study.
    Martín-Mateos RM, Graus J, Albillos A, Arocena C, Rodríguez Gandía MA, Blesa C, García-Hoz F, García González M, García-Alonso FJ, Bárcena R.
    Transplant Proc; 2012 Nov 27; 44(9):2570-2. PubMed ID: 23146457
    [Abstract] [Full Text] [Related]

  • 16. Basiliximab reduces acute liver allograft rejection in pediatric patients.
    Strassburg A, Pfister ED, Arning A, Nashan B, Ehrich JH, Melter M.
    Transplant Proc; 2002 Sep 27; 34(6):2374-5. PubMed ID: 12270443
    [No Abstract] [Full Text] [Related]

  • 17. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation.
    Gruttadauria S, Vasta F, Mandalà L, Cintorino D, Piazza T, Spada M, Verzaro R, Gridelli B.
    Transplant Proc; 2005 Sep 27; 37(6):2611-3. PubMed ID: 16182762
    [Abstract] [Full Text] [Related]

  • 18. Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell Histiocytosis.
    Braier J, Ciocca M, Latella A, de Davila MG, Drajer M, Imventarza O.
    Med Pediatr Oncol; 2002 Mar 27; 38(3):178-82. PubMed ID: 11836717
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients.
    Marino IR, Doria C, Scott VL, Foglieni CS, Lauro A, Piazza T, Cintorino D, Gruttadauria S.
    Transplantation; 2004 Sep 27; 78(6):886-91. PubMed ID: 15385809
    [Abstract] [Full Text] [Related]

  • 20. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
    Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrieta EJ, Klar E, Pageaux GP, Scudamore CH, Cuervas-Mons V, Metselaar HJ, Prestele H, Girault D.
    Liver Transpl; 2002 Feb 27; 8(2):123-31. PubMed ID: 11862588
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.